https://scholars.lib.ntu.edu.tw/handle/123456789/638100
標題: | Therapy of Primary Refractory and Relapsed Diffuse Large B-Cell Lymphoma from the Perspective in 2022 - Theoretical Basis and Clinical Case Discussion | 作者: | Yu, Ta Chuan TAI-CHUNG HUANG |
關鍵字: | Lymphoma | Recurrence | Refractory | Therapy | 公開日期: | 1-十二月-2021 | 卷: | 32 | 期: | 6 | 起(迄)頁: | 431 | 來源出版物: | Journal of Internal Medicine of Taiwan | 摘要: | Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma. Approximately 30-40% of patients with this disease do not respond well to therapy, hence with poor prognosis. The opportunity of curing these patients hinges on high-dose chemotherapy followed by autologous hematopoietic stem cell transplantation, whose intensity, however, is only tolerable to a half of this population. It is imminent to develop therapy for the patients unfit for transplant. In 2022, more and more novel therapies are being studied to treat primary refractory and relapsed DLBCL, including monoclonal antibodies (anti-CD20,-CD19,-CD79b,-CD30), Immune modulators (lenalidomide), small molecule drugs (XPO-1 inhibitor, PI3K inhibitor), immunotherapy(bispecific T-cell engager, chimeric antigen receptor T-cell therapy, immune checkpoint inhibitor). This expanding armamentarium not only brings new hopes but also challenges the physician to tailor therapy for different individuals. |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/638100 | ISSN: | 10167390 | DOI: | 10.6314/JIMT.202112_32(6).05 |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。